An Emergency Medicine Broadsheet
·Phoenix·
Est. MMXXVI
Blue Fish Med · Today's Topic
Refeeding Syndrome
Refeeding can trigger rapid intracellular electrolyte shifts, causing arrhythmia, respiratory failure, seizures, or death. Risk recognition before calories—and close monitoring afterward—are the key interventions.
Also known asrefeeding · refeeding hypophosphatemia
A 26-year-old with a BMI of 14 sits hunched beneath a thin blanket, saying that food has barely stayed down for weeks. After a day of eating again, their legs feel too weak to stand and their heart seems to flutter. The monitor shows frequent ectopic beats; the first electrolyte results are arriving. What do you check—and how quickly do you act?
— What’s your move? Read on.
Before you read
Which electrolyte shift can turn weakness into respiratory or cardiac failure?
What is the safest way to restart calories?
When to Think of It
Consider refeeding syndrome after nutrition is restarted in someone with prolonged poor intake, major weight loss, low BMI, or alcohol use disorder. A falling phosphate is characteristic; hypokalemia, hypomagnesemia, edema, weakness, delirium, and arrhythmia may accompany it.
Sick or Not Sick
The pivotal call is whether this is high-risk refeeding with significant electrolyte depletion or organ dysfunction. Severe electrolyte abnormalities, ECG changes, respiratory compromise, or neurologic symptoms call for monitored inpatient care, often ICU-level depending on instability.
The First Fifteen Minutes
Obtain phosphate, potassium, magnesium, glucose, renal function, ECG, and fluid status; repeat electrolytes frequently during early feeding.
If malnourished or at risk and carbohydrate is being given: thiamine 100 mg IV or PO before feeding/dextrose and daily for at least 5–7 days; it supports carbohydrate metabolism and reduces risk of thiamine-related neurologic injury.
If phosphate is severely low (<1 mg/dL), symptomatic, or there is organ dysfunction: sodium or potassium phosphate 0.16–0.32 mmol/kg IV over 4–6 hours; it restores phosphate needed for cellular energy. Dose and salt selection depend on renal function, potassium, and local protocol—check an institutional reference.
If severe/symptomatic hypomagnesemia: magnesium sulfate 1–2 g IV, with repeat dosing guided by level, symptoms, and renal function; magnesium replacement corrects deficiency and helps stabilize cardiac and neuromuscular function.
If potassium is low: potassium chloride 10 mEq IV per hour peripherally (up to 20 mEq/hour centrally with continuous ECG monitoring), or oral replacement when appropriate; it restores membrane potential and reduces arrhythmia risk. Adjust for renal function and local protocol.
Do not delay urgently needed glucose for thiamine; give thiamine as soon as possible.
Definitive Care & Disposition
Start nutrition cautiously—commonly 10–20 kcal/kg in the first 24 hours, with lower starts for extreme risk—and advance gradually over several days as electrolytes remain stable. Restrict excess sodium/fluid when edema or cardiac strain is present; monitor intake, output, weight, glucose, and electrolytes closely. Admit patients with significant derangements, symptoms, or need for IV replacement; use telemetry for arrhythmias or substantial electrolyte abnormalities.
How This One Kills
Advancing calories despite a rapidly falling phosphate can cause diaphragmatic weakness and respiratory failure before the team recognizes the deterioration.
The Differential — What Else Looks Like This
Sepsis — fever/infection and persistent vasodilatory physiology may explain tachycardia; mistaking it for a nutrition-related shift can delay source control.
Diabetic ketoacidosis — acidosis and hyperglycemia distinguish it; treating only the glucose while overlooking phosphate and potassium shifts can worsen weakness.
The Second-Day Story
The classic picture may be absent: an older adult may present with falls, confusion, edema, or new oxygen need rather than a clear history of starvation. Ask about recent intake and weight loss, inspect for muscle/fat wasting, and compare electrolytes with values before feeding; a normal initial phosphate does not rule out depletion that becomes apparent after calories restart.
Back to Our Patient
Back to our 26-year-old: the markedly low BMI and weeks of poor intake put refeeding syndrome on the table, and weakness with ectopy makes this a high-risk presentation. Check phosphate, potassium, magnesium, glucose, renal function, and ECG immediately; give thiamine before ongoing carbohydrate exposure, replace severe abnormalities with monitored dosing, and do not advance calories rapidly. Admit for close electrolyte and cardiac monitoring, escalating level of care if arrhythmia or respiratory compromise develops.
Patient Presentation to Attending
How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling
“This is a 26-year-old with weeks of minimal intake and marked weight loss, now with weakness and palpitations after eating more over the past day. They report nausea and poor intake but no fever, diarrhea, or chest pain. They are markedly underweight, weak on standing, and have frequent ectopy on the monitor. I’m concerned for refeeding syndrome with clinically significant electrolyte depletion; phosphate, potassium, magnesium, glucose, renal function, and an ECG are being checked now. I’ll give thiamine, replace severe abnormalities with ECG monitoring, and avoid rapid calorie advancement. They need admission for serial electrolytes and telemetry, with escalation if instability develops.”
Study Directive
From memory, list five refeeding risk factors and the three electrolytes to trend.
Write a first-day monitoring and calorie-advancement plan for a high-risk adult; verify replacement doses against your hospital protocol.
Review your institution’s threshold for telemetry and ICU consultation in severe electrolyte depletion.
Treating opioid use disorder in the ED can reduce withdrawal and create a bridge to ongoing care. Starting medication too early can precipitate withdrawal;...
Also known asopioid use disorder · OUD · opioid dependence · opioid addiction
A 32-year-old keeps shifting on the stretcher, rubbing their arms as gooseflesh rises beneath the fluorescent light. Their eyes are watery, their stomach is cramping, and they say they last used fentanyl yesterday. They ask for help stopping, but they are worried that the first dose could make everything worse. What finding tells you it is safe to begin?
Before You Read
How do you distinguish withdrawal from intoxication that still threatens ventilation?
What bedside finding should guide buprenorphine timing?
What is the practical first dose in the ED?
Why It Matters
Treating opioid use disorder in the ED can reduce withdrawal and create a bridge to ongoing care. Starting medication too early can precipitate withdrawal; delaying treatment until a distant appointment can lose the moment when the patient is ready.
When to Think of It
Suspect opioid withdrawal with yawning, lacrimation, rhinorrhea, mydriasis, piloerection, diarrhea, vomiting, diffuse aches, and restlessness after reducing or stopping opioids. Use the Clinical Opiate Withdrawal Scale (COWS) to structure severity; first exclude ongoing sedation or respiratory depression.
Sick or Not Sick
The crucial call is withdrawal and awake versus intoxicated or sedated with impaired ventilation. Treat airway and breathing first if the patient is not reliably awake or is hypoventilating; do not give buprenorphine to someone who remains significantly sedated.
The First Fifteen Minutes
Check vitals, mental status, respiratory effort, last opioid exposure, and COWS; ask about methadone, long-acting opioids, benzodiazepines, and alcohol.
If opioid-related hypoventilation is present: naloxone 0.04–0.4 mg IV, titrated every 2–3 minutes to adequate ventilation; if IV access is unavailable, 4 mg intranasal, repeated every 2–3 minutes as needed. Titration reverses respiratory depression while reducing abrupt severe withdrawal.
If awake with objective, clinically significant withdrawal (commonly COWS ≥8–12) and no ongoing sedation: buprenorphine/naloxone 8 mg/2 mg sublingually; reassess in 30–60 minutes and give another 4–8 mg/1–2 mg if withdrawal persists. Buprenorphine’s partial agonism relieves withdrawal and craving. Thresholds and dosing vary by protocol, particularly with fentanyl exposure—check your local pathway.
Definitive Care & Disposition
Continue induction to symptom control, often 16–24 mg buprenorphine on day one; arrange rapid follow-up, a bridge prescription when appropriate, and naloxone access. Discuss treatment goals without requiring abstinence as a condition of care. Consider specialist input for pregnancy, complex sedative co-use, or difficult induction.
How This One Kills
Giving buprenorphine before sufficient withdrawal—especially after fentanyl or a long-acting opioid—can displace full agonists and precipitate abrupt, severe withdrawal.
The Atypical Presentation
Fentanyl exposure, long-acting formulations, or co-use of sedatives can blur timing and signs; a patient may report severe withdrawal while appearing drowsy, or have a modest COWS despite distress. Trust the exam and serial reassessment over the clock alone, clarify other substances, and do not start buprenorphine until the patient is alert and objective withdrawal is present.
Back to Our Patient
Back to our 32-year-old: first confirm they are awake, ventilating normally, and not intoxicated; the watery eyes, piloerection, and gastrointestinal symptoms support withdrawal. A COWS assessment and medication history establish whether withdrawal is sufficient for induction. If it is, start 8 mg/2 mg buprenorphine/naloxone sublingually, reassess and titrate to symptoms, then arrange ongoing treatment and discharge naloxone; admit if another medical or safety issue requires it.
Patient Presentation to Attending
“This is a 32-year-old reporting fentanyl use yesterday who presents requesting help with cessation and now has diffuse aches, abdominal cramping, watery eyes, and gooseflesh. They deny alcohol or benzodiazepine use and have no reported methadone exposure. They are alert, not somnolent, and breathing normally, with mydriasis, lacrimation, and piloerection. The exam supports opioid withdrawal rather than intoxication; I’m obtaining a COWS score and confirming the last use and co-ingestants. If objective withdrawal is sufficient, I’ll start 8 mg/2 mg sublingual buprenorphine/naloxone and reassess. I’ll arrange a bridge to ongoing treatment and provide naloxone; admission depends on any emerging medical or safety concern.”
Study Directive
Practice scoring COWS on a case vignette and state your local induction threshold from memory.
Write a one-minute ED buprenorphine plan that includes reassessment, follow-up, and naloxone.
Review your institution’s approach to induction after fentanyl exposure.
Naloxone: 0.04–0.4 mg IV titrated to ventilation; 4 mg intranasal, repeat every 2–3 minutes if needed. Pediatric reversal is weight-based and should follow a pediatric protocol.
A COWS score supports—but does not replace—the decision that the patient is awake and in genuine withdrawal.
Treat the patient’s stated goal as an opening for treatment, not a requirement that they promise abstinence.
The Mimics
Opioid intoxication — somnolence and hypoventilation rather than autonomic activation; buprenorphine during significant sedation can compound risk.
Alcohol/benzodiazepine withdrawal — tremor, perceptual disturbance, or seizures may dominate; missing it delays potentially lifesaving withdrawal treatment.
Gastroenteritis — vomiting and diarrhea without the characteristic autonomic signs; mislabeling it can lead to inappropriate medication initiation.
Board Question
A patient with opioid use disorder is alert and has objective withdrawal after stopping short-acting opioids. Which is the best next step? -
AStart buprenorphine once clinically significant withdrawal is established -
BGive extended-release naltrexone immediately -
CWait until the patient has completed several weeks of abstinence -
DGive naloxone to prevent withdrawal
Reveal answer
Correct: A
Buprenorphine can be started when objective withdrawal is established, with timing guided by the clinical exam and local protocol. Naltrexone requires an opioid-free interval, and naloxone is for opioid toxicity—not withdrawal prevention.
Surviving an overdose is a high-risk moment and an opportunity to connect the patient with effective treatment. Reversal alone does not treat opioid use...
Also known asopioid use disorder · OUD · opioid dependence · opioid addiction
A 41-year-old opens their eyes beneath the ambulance bay lights, coughing as a paramedic removes the oxygen mask. Their partner says they found them unresponsive and blue beside a phone; now they are awake but sweating and nauseated. They say this has happened before and ask whether there is any help beyond getting through tonight. What is the safest next step?
Before You Read
What must be stable before you address ongoing treatment?
When can buprenorphine be considered after reversal?
Which discharge intervention can protect the patient and their household immediately?
Why It Matters
Surviving an overdose is a high-risk moment and an opportunity to connect the patient with effective treatment. Reversal alone does not treat opioid use disorder or protect against a recurrent overdose after discharge.
When to Think of It
Consider opioid toxicity with depressed mental status and hypoventilation; pinpoint pupils may be present but are not required. After reversal, reassess for recurrent sedation, co-ingestants, complications, and emerging withdrawal. A patient who is awake and requests help may be ready to discuss treatment.
Sick or Not Sick
The single fork is ongoing or recurrent respiratory depression versus sustained clinical recovery. Persistent hypoventilation, repeated naloxone need, long-acting exposure, complications, or concerning co-ingestion requires continued observation and often admission.
The First Fifteen Minutes
Support airway and ventilation; check glucose, temperature, trauma, co-ingestants, and response durability. Do not equate waking up with being medically clear.
If respiratory depression recurs: naloxone 0.04–0.4 mg IV, titrated every 2–3 minutes to adequate ventilation; if IV access is unavailable, 4 mg intranasal, repeated every 2–3 minutes as needed. Naloxone reverses opioid-mediated respiratory suppression; some patients need repeat dosing or infusion.
If fully awake, medically stable, and in objective withdrawal: offer buprenorphine/naloxone 8 mg/2 mg SL, with reassessment in 30–60 minutes and further 4–8 mg/1–2 mg SL if symptoms persist. It treats withdrawal and begins ongoing care; induction thresholds and higher-dose approaches vary, so follow local protocol.
If not yet in withdrawal or the patient declines buprenorphine: do not force induction; offer take-home naloxone and rapid follow-up.
Definitive Care & Disposition
Observe according to exposure, naloxone requirement, and recurrence risk; longer-acting opioids or repeated reversal warrant longer monitoring. Offer take-home naloxone with a brief overdose-response demonstration, safer-use counseling, and a direct handoff or rapid appointment for ongoing medication treatment. Admission is appropriate for recurrent toxicity, significant complications, unsafe recovery, or unresolved medical and psychiatric risks.
How This One Kills
Discharging after a brief awakening without accounting for naloxone wearing off can leave a patient vulnerable to recurrent respiratory depression.
The Atypical Presentation
A patient may be awake after naloxone but still have residual sedation, hypoxia, aspiration, or an unrecognized co-ingestant. Conversely, fentanyl exposure may be reported incompletely, and withdrawal may emerge only after observation. Reassess breathing and mental status over time, obtain collateral when possible, and base disposition on sustained recovery—not a single post-reversal snapshot.
Back to Our Patient
Back to our 41-year-old: stabilize and observe after reversal first, confirming sustained normal ventilation and checking for complications or co-ingestants. If alert and in objective withdrawal, offer buprenorphine/naloxone and reassess; if not yet withdrawing, do not force an induction. Provide take-home naloxone, teach its use, and make a direct connection to ongoing treatment. Admit if sedation recurs, repeat reversal is required, or another medical concern remains.
Patient Presentation to Attending
“This is a 41-year-old found unresponsive with cyanosis, now awake after prehospital reversal, requesting help with recurrent opioid use. Their partner found them unresponsive; the exact substance and co-ingestants are not yet confirmed. They are now alert and breathing spontaneously, but I’m reassessing for recurrent sedation, hypoxia, trauma, and aspiration. I’ll check glucose and observe based on the suspected exposure and response to reversal. If they remain stable and develop objective withdrawal, I’ll offer buprenorphine; regardless, they need take-home naloxone and a direct treatment connection. Admission is indicated if respiratory depression recurs or a complication or co-ingestion is identified.”
Study Directive
Rehearse a post-overdose reassessment checklist, including recurrence, trauma, hypoxia, and co-ingestants.
Demonstrate how to teach a family member intranasal naloxone use in under one minute.
Review your local observation and admission criteria after naloxone reversal.
Key Medications
Naloxone: 0.04–0.4 mg IV titrated every 2–3 minutes to ventilation; 4 mg intranasal, repeat every 2–3 minutes as needed. For recurrent toxicity, infusion is commonly started at two-thirds of the effective reversal dose per hour; calculation and titration vary—check toxicology or institutional guidance.
Buprenorphine/naloxone: 8 mg/2 mg SL when alert, stable, and in objective withdrawal; reassess at 30–60 minutes and titrate per protocol.
Naloxone’s endpoint is adequate ventilation, not necessarily full alertness.
Provide overdose-response instruction with take-home naloxone; a device without practical teaching may not be used effectively.
The Mimics
Benzodiazepine or sedative intoxication — often less responsive to naloxone; attributing persistent coma to opioids alone delays airway protection and evaluation.
Hypoglycemia — a bedside glucose identifies a rapidly reversible cause; missing it prolongs neurologic injury.
Intracranial injury — focal findings or trauma history argue for a structural cause; premature attribution to overdose can miss a time-critical lesion.
Board Question
A patient remains somnolent with recurrent hypoventilation after an initial naloxone response. What is the best next step? -
ADischarge once the patient briefly awakens -
BContinue ventilatory support and titrate naloxone, considering infusion for recurrent toxicity -
CGive buprenorphine immediately -
DGive flumazenil empirically
Reveal answer
Correct: B
Naloxone may wear off before the opioid, and recurrent hypoventilation requires continued respiratory support and repeat titration; an infusion may be needed. Brief awakening is not sufficient for safe discharge.
Methadone and buprenorphine are established opioid agonist treatments; ED care should connect patients with ongoing treatment rather than stop at withdrawal management.
Tobacco dependence drives preventable cardiovascular, pulmonary, and cancer morbidity, and an acute-care visit can create a practical opening for change....
Also known astobacco cessation · quit smoking · tobacco use disorder · nicotine dependence
A 58-year-old pauses between sentences to catch their breath, then steps toward the open ED doorway and pats their coat for a lighter. They have smoked for decades and say they have tried to quit twice, but the cravings were overwhelming. Before they leave, they ask whether there is anything that might make another attempt different. What will you offer?
Before You Read
How can you turn an ED encounter into a useful quit attempt without lecturing?
Which medication combinations can address both baseline and breakthrough cravings?
What history rules out a common prescription option?
Why It Matters
Tobacco dependence drives preventable cardiovascular, pulmonary, and cancer morbidity, and an acute-care visit can create a practical opening for change. Brief advice plus medication and follow-up is more useful than advice alone.
When to Think of It
Ask every patient who smokes about readiness, prior quit attempts, and what made them relapse. Treat tobacco use disorder as a chronic, relapsing condition; a patient who is not ready to quit may still accept a reduction goal or future follow-up.
Sick or Not Sick
The key decision is which cessation option is safe and acceptable for this patient. Check pregnancy status when relevant, seizure/eating-disorder history, renal function for varenicline adjustment, medication interactions, and patient preference.
The First Fifteen Minutes
Ask permission to discuss smoking, give clear brief advice to quit, and offer medication plus follow-up; avoid shame or an all-or-nothing approach.
If the patient wants to quit and smokes >10 cigarettes/day: nicotine patch 21 mg transdermal daily; if they smoke ≤10/day, 14 mg daily is a typical start. Add gum for breakthrough cravings—4 mg if the first cigarette is within 30 minutes of waking, otherwise 2 mg, every 1–2 hours as needed, maximum 24 pieces/day. The patch provides steady nicotine and gum treats episodic craving.
If they prefer a prescription option and have no contraindication: varenicline 0.5 mg PO daily on days 1–3, 0.5 mg twice daily on days 4–7, then 1 mg twice daily; it reduces craving and the rewarding effect of smoking. Start about one week before the quit date; adjust for renal impairment.
If appropriate and preferred, with no seizure disorder, current/prior eating disorder, or other contraindication: bupropion SR 150 mg PO daily for 3 days, then 150 mg twice daily, with doses at least 8 hours apart; it reduces withdrawal symptoms and craving. Start 1–2 weeks before the quit date.
Select one strategy with the patient; do not prescribe all options together.
Definitive Care & Disposition
Set a quit date or specific next step, arrange follow-up within 1–2 weeks, and connect to counseling or a quitline. Continue cessation medication for the usual treatment course—often 8–12 weeks or longer depending on response and product—and reassess cravings, adherence, adverse effects, and relapse. NRT combination therapy is a reasonable option when a single product has not controlled cravings.
How This One Kills
Giving vague advice without medication access or follow-up leaves nicotine withdrawal unaddressed and makes relapse more likely.
The Atypical Presentation
Some patients deny “smoking” because they vape, use cigars, or smoke intermittently; others are not ready to quit but are willing to reduce or discuss future options. Ask neutrally about all nicotine products and prior attempts, offer help without requiring a quit commitment, and revisit the conversation at later encounters.
Back to Our Patient
Back to our 58-year-old: acknowledge the prior difficult quit attempts, ask whether they are ready to try again, and offer a concrete option rather than a lecture. If they smoke more than 10 cigarettes daily and want treatment, combination patch plus gum can address steady and breakthrough cravings; varenicline or bupropion are alternatives after checking contraindications and preferences. Set a quit date or next step, provide follow-up, and discharge with a plan the patient accepts.
Patient Presentation to Attending
“This is a 58-year-old long-term smoker with chronic breathlessness who is interested in help quitting after two unsuccessful attempts. They describe cravings as the main reason they returned to smoking and are asking about treatment today. They are currently able to speak in sentences, with no reported acute chest pain or abrupt change in respiratory symptoms. I’ve asked about daily cigarette use, time to first cigarette, prior medication trials, seizure or eating-disorder history, and preference. I recommend offering combination nicotine replacement or a prescription option selected with the patient, plus a quit date and follow-up within one to two weeks. I’ll also ensure any acute respiratory or cardiac complaint is evaluated independently of the cessation plan.”
Study Directive
Memorize the nicotine patch starting dose by cigarettes per day and gum dose by time to first cigarette.
Practice a 30-second, permission-based quit conversation that includes medication and follow-up.
Name three contraindication checks before prescribing bupropion and one renal consideration for varenicline.
Key Medications
Nicotine patch: 21 mg/day if >10 cigarettes/day; 14 mg/day if ≤10/day. Typical step-down schedules vary by product.
Nicotine gum: 2 or 4 mg every 1–2 hours as needed, max 24 pieces/day; chew-and-park technique improves absorption.
Varenicline: 0.5 mg daily ×3 days, then 0.5 mg twice daily ×4 days, then 1 mg twice daily; reduce dose for significant renal impairment.
Bupropion SR: 150 mg daily ×3 days, then 150 mg twice daily, at least 8 hours apart; avoid in seizure disorder, current/prior eating disorder, and other labeled contraindications.
Pediatric cessation pharmacotherapy is individualized; consult a pediatric or institutional guideline.
High-Yield Pearls
Ask how soon after waking the patient smokes; it helps choose 2 mg versus 4 mg nicotine gum.
Bupropion is not an appropriate choice with a seizure disorder or current/prior eating disorder.
The Mimics
Nicotine withdrawal — irritability, poor concentration, and craving after stopping; mistaking it for a primary psychiatric deterioration can lead to inappropriate care.
Acute coronary syndrome — chest discomfort with ischemic features requires cardiac evaluation; attributing it to anxiety or nicotine craving risks missing infarction.
COPD exacerbation — increased dyspnea, sputum, or wheeze suggests acute respiratory disease; cessation counseling must not replace treatment of the exacerbation.
Board Question
A patient smokes 15 cigarettes daily and wants to quit. They report strong breakthrough cravings despite using a nicotine patch. Which adjustment is most appropriate? -
AAdd short-acting nicotine gum to the patch -
BStop all nicotine replacement immediately -
CAdd bupropion without checking contraindications -
DUse nicotine gum continuously without a daily maximum
Reveal answer
Correct: A
A patch provides steady nicotine, while short-acting gum can address breakthrough cravings. Screen for contraindications and teach proper gum use and dosing limits.
Offer adults who smoke behavioral counseling and FDA-approved cessation medication; for pregnant patients, prioritize behavioral counseling because evidence for medication is insufficient.
A quick test of recall from prior editions. Commit to an answer before you check.
From yesterday's edition
A 58-year-old man arrives at 0300 reporting two days of intermittent substernal pressure with exertion, each episode lasting ten minutes and resolving on its own. He has been pain-free for ninety minutes. What’s the diagnosis, and the first move?
Check your answer
Wellens Syndrome. Recognize, then disposition: aspirin and anticoagulation per local ACS pathway, urgent cardiology consult, and admit for catheterization. Do not discharge a pain-free patient with Wellens morphology, even if the troponin is negative.
From the September 26 edition
Today, three days ago: Calcium Chloride. What’s the adult ED dose, and the contraindication you’d most regret missing?
Check your answer
1 g IV of 10% calcium chloride, preferably through central line; may repeat based on ECG/hemodynamics/ionized calcium. Peripheral administration carries tissue necrosis risk with extravasation; caution in digoxin toxicity and hypercalcemia.
From the September 19 edition
A patient with chronic lithium therapy presents with confusion, ataxia, and a lithium concentration of 3.2 mEq/L. Creatinine is elevated, and the level is expected to remain above 1 mEq/L for more than 36 hours despite IV fluids. What is the best next step?
AActivated charcoal
BUrgent intermittent hemodialysis
CFurosemide-induced diuresis
DFlumazenil
Reveal answer
Correct · B
Urgent intermittent hemodialysis. Lithium is not effectively bound by charcoal, and forced diuresis is unreliable and potentially dangerous. Significant neurologic toxicity, renal impairment, and prolonged clearance are indications for extracorporeal removal.
Journal Watch
From the FOAMed wire
Notable posts and reviews from the last week, ranked by relevance to today’s lead and source trust.
🧭 REBEL Rundown 🗝️ Key Points 👀 HINTS requires the right patient: Ongoing acute vestibular syndrome with nystagmus—and a trained examiner. 🧮 Sudbury assesses broader risk: It estimates the likelihood of serious central diagnoses in patients with dizziness, vertigo, or...
Today on the emDOCs cast, Cameron Upchurch covers distal radial arterial lines. The post emDOCs Podcast – Episode 149: Distal Radial Arterial Lines appeared first on emDocs .
Podcast Picks
Two for the shift
Critical Care Perspectives in Emergency Medicine2026-09-01
Brain damage and death from ischemic encephalopathy is common after cardiac arrest. Animal studies and limited observational studies suggest that high oxygen exposure after ROSC may result in neuronal death. As such, it is hypothesized that limiting oxygen exposure (conservative oxygen) many attenuate reperfusion injury and improve outcomes. At present,...
Source
Critical Care Perspectives in Emergency Medicine
Published
2026-09-01
Host
Critical Care Perspectives in Emergency Medicine, Critical Care Perspectives in Emergency Medicine
Meet L.I.F.T. (Low acuity, Immediate care, Fast track, and Telehealth)! September topics include chest pain, seizures, PID, migraine guidelines, and pediatric swollen joints. 1. September Introduction: Meet L.I.F.T....
Critical Care Corner
Matched to today’s topics
A critical-care reference from LITFL’s Critical Care Compendium, tied to today’s differential.
Restarting nutrition in a severely malnourished patient can precipitate hypophosphatemia, arrhythmias, and respiratory failure; thiamine and close electrolyte monitoring are key to safe refeeding.
Refeeding Syndrome = a group of clinical findings that occur in severely malnourished individuals undergoing nutritional support.
Pharmacology Corner
Two drugs for the shift
One antimicrobial and one other ED workhorse — selected daily, with sources and last-reviewed dates so every dose is cross-checkable.
Antimicrobial of the Day
Fosfomycin
Phosphonic acid urinary antibacterial
Indication
Single-dose treatment of uncomplicated cystitis, including many MDR uropathogens (ESBL-producing E. coli, VRE) in the lower urinary tract.
What’s your dose? — reveal dosing & cautions
ED Dose
3 g PO as a single dose, dissolved in water (sachet). Some complicated-cystitis regimens use 3 g q48–72h x3 doses.
Renal Adjustment
Single-dose cystitis generally does not require adjustment; limited data in advanced CKD.
Contraindications
Hypersensitivity to fosfomycin.
Interactions
Metoclopramide and other prokinetics reduce serum/urinary concentrations.
Monitoring
Clinical response; GI tolerance.
ED Pearl
A one-time 3 g sachet maximizes adherence and retains activity against many ESBL/MDR uropathogens — but it is a lower-UTI agent only and has no role in pyelonephritis.
Rate control for atrial fibrillation/flutter with RVR in selected hemodynamically stable patients without severe HFrEF, preexcitation, or shock.
What’s your dose? — reveal dosing & cautions
ED Dose
0.25 mg/kg IV over 2 min; if needed 0.35 mg/kg IV after 15 min. Infusion 5–15 mg/h titrated to rate/BP. Some EDs use lower initial boluses to avoid hypotension.
Renal Adjustment
No renal adjustment; use caution in hepatic impairment.
Contraindications
Preexcited AF/WPW, severe hypotension/shock, 2nd/3rd degree AV block without pacer, severe HFrEF/decompensated heart failure.
For educational use only. Verify dosing against the FDA label and your institution’s pharmacy resources before administering.
ECG of the Day
Ischemia
MI Localization by Lead Groups
Mapping ST changes onto lead groups tells you which wall is infarcting and which artery is occluded — the mental model that turns a 12-lead into a coronary angiogram.
The Tracing
A 66-year-old woman with an hour of crushing chest pain and diaphoresis is brought to a resus bay. As the 12-lead prints, you make yourself read it by territory rather than lead by lead: the inferior group (II, III, aVF), the lateral group (I, aVL, V5-6), the anteroseptal precordium (V1-4), and aVR. You are looking for where a wave of ST elevation clusters and where reciprocal depression falls opposite it, so you can name the wall at risk before the troponin returns. The tracing in front of you shows changes concentrated in one of these groups, and the pattern is pointing you toward a specific culprit vessel.
Group the 12 leads by territory: inferior (II, III, aVF), lateral (I, aVL, V5-6), anteroseptal (V1-4), and aVR
Anterior/anteroseptal changes localize to the LAD territory
Inferior changes localize to the inferior wall (typically RCA or circumflex)
Lateral changes point to LAD or circumflex branch territory; high lateral changes to I and aVL
Posterior involvement is inferred from reciprocal anterior changes and confirmed with posterior leads
Pearls
Reading by lead group rather than lead by lead is what lets you predict the culprit vessel and the volume of myocardium at risk before angiography.
Reciprocal depression opposite a territory helps confirm a true injury current, so always check the leads that face away from the suspected wall.
The territories overlap at their edges — lateral extension of an inferior or anterior MI signals a larger infarct — so localize, then look for extension into adjacent walls.
Pitfalls
Anchoring on a single lead's ST change misses the territorial pattern; a finding is far more convincing when the whole lead group moves together.
Posterior and right ventricular infarcts hide from the standard 12-lead and must be actively sought with posterior and right-sided leads.
Treating localization as academic delays action — the point of naming the wall is to trigger reperfusion for the corresponding STEMI, not to file a diagnosis.
At the Bedside
Use the lead-group map to convert ST changes into a wall and a suspected artery, then act on that territory: activate the cath lab for a localized STEMI and add posterior or right-sided leads when the pattern hints at a hidden territory.
For educational use only. Verify ECG interpretation against the LITFL entry and your institution’s practice before clinical decision-making.
Case of the Day
From the lead · Refeeding Syndrome
Self-Examination
Test Your Understanding
A malnourished patient develops weakness and ventricular ectopy after nutrition is restarted. Which electrolyte abnormality is most characteristic of refeeding syndrome? -
AHyperphosphatemia -
BHypophosphatemia -
CHypermagnesemia -
DHypercalcemia
Reveal answer
Correct answer · B
Insulin-driven intracellular uptake after carbohydrate reintroduction can sharply lower serum phosphate. Potassium and magnesium may also fall and contribute to cardiac or neuromuscular complications.
Study Pace4 topics today; Issue 77 of 94 — Psychiatry (Week 43)Deadline · June 1, 2026